
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health Inc demonstrated strong financial performance, with a notable 6.3% growth in gross margin dollar generation in the latest quarter. The company also exhibited robust capital management by repurchasing $95 million of its own stock, reflecting confidence in its future prospects. Additionally, the chronic therapy segment experienced growth exceeding 10%, alongside an upward revision of key elements in the FY/25 financial guidance, signaling positive momentum for sustained revenue growth and margin expansion.
Bears say
The financial outlook for Option Care Health Inc is negatively impacted by uncertainty regarding the future revenue implications of the Stelara biosimilar, which may result in a gross profit headwind of $25 million to $35 million. Additionally, the company’s reliance on its largest customer, which accounts for 14% of total revenue, poses a significant risk, as losing this account could substantially affect overall profitability. Furthermore, limited gross margin expansion is anticipated due to the growth dynamics of chronic therapies compared to higher-margin acute therapies, challenging future EBITDA margin improvements.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares